Abstract
Reactive oxygen species via NADPH oxidase (NOX) activation are involved in the pathogenesis of many disease conditions such as diabetes and its complications. In the present study, we have examined the effect of daidzein in the management of diabetic cystopathy. Diabetes was induced in male Sprague Dawley rats via intraperitoneal injection of streptozotocin (STZ) at a dose of 55mg/kg. After 6weeks of diabetes induction, animals were treated with daidzein orally at a dose of 25, 50, and 100mg/kg for 4weeks. Diabetic animals showed increase (p < 0.001) in bladder capacity (4.32 ± 0.43mL) and residual volume (2.53 ± 0.19mL) when compared with normal control animals (2.10 ± 0.40mL and 0.51 ± 0.12mL res). Treatment with daidzein at dose of 50 and 100mg/kg significantly reduced the elevated bladder capacity (2.91 ± 0.11mL, p < 0.01 and 2.65 ± 1.13mL, p < 0.001) and residual volume (1.40 ± 0.15mL, p < 0.001 and 1.15 ± 0.05mL, p < 0.001). Daidzein-treated animals also showed improvement in voiding efficiency. Elevated threshold and baseline pressure were also found to be reduced in diabetic animals after 4weeks of daidzein treatment. Daidzein treatment also prevented the loss of antioxidant enzymes in the urinary bladder and also reduced the expression of NOX-4 and RAC-1 in the bladder. From the results, it can be concluded that daidzein showed a beneficial effect on urinary bladder dysfunction in diabetic animals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.